Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis

Clinical Infectious Diseases

Volumn 50, Issue 9, 2010, Pages 1288-1299

  Khan, Faiz A ^a   Minion, Jessica ^a   Pai, Madhukar ^a,b   Royce, Sarah ^c   Burman, William ^d   Harries, Anthony D ^e,f   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DENVER PUBLIC HEALTH   (United States)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RIFABUTIN; RIFAMYCIN;

ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DOSAGE SCHEDULE COMPARISON; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; MIXED INFECTION; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; SCREENING; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS; VIROTHERAPY;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; COHORT STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RIFAMPIN; TREATMENT FAILURE; TUBERCULOSIS;

EID: 77950971430     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651686     Document Type: Article

References (67)

1. WHO. Global Tuberculosis Control: Epidemiology, strategy, financing. WHO/HTM/TB/2009.411.
2. Korenromp EL, Scano F, Williams BG, Dye C, Nunn P. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after ritampin-based treatment: an analytical review. Clin Infect Dis 2003; 37(1): 101-112. (Pubitemid 36836652)
3. Mallory KF, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000; 4(5): 455-462. (Pubitemid 30256849)
4. Dlodlo RA, Fujiwara PI, Enarson DA. Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals? Eur Respir J 2005; 25(4): 751-757.
5. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001; 32(4): 623-632. (Pubitemid 32565005)
6. Pulido F, Pena JM, Rubio R, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997; 157(2): 227-232. (Pubitemid 27058159)
7. El Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998; 26(5): 1148-1158.
8. Perriens J, St Louis ME, Mukadi YB, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332(12): 779-784.
9. Harries AD, Chimzizi RB, Nyirenda TE, van Gorkom J, Salaniponi FM. Preventing recurrent tuberculosis in high HIV-prevalent areas in sub-Saharan Africa: what are the options for tuberculosis control programmes? Int. J Tuberc Lung Dis 2003; 7(7): 616-622.
10. WHO. Treatment of tuberculosis: guidelines for national treatment programmes. WHO/CDS/TB. 2004; 2003.313(3rd edition).
11. Centers for Disease Control and Prevention. Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52(RR-11).
12. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366(9483): 378-384. (Pubitemid 41073955)
13. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359(9323): 2059-2064. (Pubitemid 34680968)
14. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19(18): 2109-2116. (Pubitemid 41668999)
15. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20(12): 1605-1612. (Pubitemid 44162402)
16. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21(6): 713-719. (Pubitemid 46568628)
17. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002; 31(1): 150-153. (Pubitemid 34284917)
18. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-Tuberculosis Drug Resistance in the World: Report No. 4. 2008;WHO/HTM/TB/2008.394.
19. Hamza T, van Houwelingen H, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008; 61(1): 41-51. (Pubitemid 350236698)
20. Higgins JP, Thompson SG, Deeks JJ, Altaian DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-560.
21. Glasziou PP, Sanders SL. Investigating causes of heterogeneity in systematic reviews. Stat Med 2002; 21(11): 1503-1511.
22. Thompson S, Sharp S. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-2708. (Pubitemid 29481404)
23. Durban Immunotherapy Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354(9173): 116-119.
24. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 1995; 345(8950): 607-610.
25. Akksilp S, Karnkawinpong O, Wattanaamomkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007; 13(7): 1001-1007. (Pubitemid 47048071)
26. Colmenero JD, Garcia-Ordonez MA, Sebastian MD, et al. Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis [in Spanish]. Enferm Infecc Microbiol Clin 1997; 15(3): 129-133.
27. Daniel OJ, Alausa OK. Treatment outcome of TB/HIV positive and TB/HIV negative patients on directly observed treatment, short course (DOTS) in Sagamu, Nigeria. Niger J Med 2006; 15(3): 222-226.
28. Domoua K, N'Dhatz M, Coulibaly G, et al. Efficacy of a short 6 month therapeutic course for HIV infected tuberculosis patients in Abidjan, Cote d'Ivoire [in French]. Bull Soc Pathol Exot 1998; 91(4): 312-314.
29. Glynn JR, Wamdorff DK, Fine PEM, Munthali MM, Sichone W, Ponnighaus JM. Measurement and determinants of tuberculosis outcome in Karonga District, Malawi. Bull World Health Organ 1998; 76(3): 295-305. (Pubitemid 28394063)
30. Harries AD, Nyangulu DS, Kang'ombe C, et al. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi. Trans R Soc Trop Med Hyg 1998; 92(3): 343-347.
31. Ige OM, Sogaolu OM, Odaibo GN, Olaleye OD. Evaluation of modified short course chemotherapy in active pulmonary tuberculosis patients with human immunodeficiency virus infection in University College Hospital, Ibadan, Nigeria-a preliminary report. Afr J Med Med Sci 2004; 33(3): 259-262.
32. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364(9441): 1244-1251. (Pubitemid 39311345)
33. Johnson JL, Okwera A, Nsubuga P, et al. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 2000; 4(11): 1032-1040.
34. Joloba ML, Johnson JL, Namale A, et al. Quantitative sputum badllary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4(6): 528-536. (Pubitemid 30409169)
35. Kassim S, Sassan Morokro M, Ackah A, et al. Two-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9(10): 1185-1191.
36. Kelly PM, Cumming RG, Kaldor JM. HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year follow-up. Trans R Soc Trop Med Hyg 1999; 93(3): 287-293.
37. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22(5): 827-833. (Pubitemid 26255603)
38. Klautau GB, Kuschnaroff TM. Clinical forms and outcome of tuberculosis in HIV-infected patients in a tertiary hospital in Sao PauloBrazil. Braz J Infect Dis 2005; 9(6): 464-478.
39. Mwaungulu FB, Floyd S, Crampin AC, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004; 82(5): 354-363. (Pubitemid 38715072)
40. Noeske J, Nguenko PN. Impact of resistance to anti-tuberculosis drugs on treatment outcome using World Health Organization standard regimens. Trans R Soc Trop Med Hyg 2002; 96(4): 429-433. (Pubitemid 37362031)
41. Okwera A, Johnson JL, Luzze H, et al. Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. Int J Tuberc Lung Dis 2006; 10(1): 39-44. (Pubitemid 43266275)
42. Ribera E, Azuaje C, Lopez RM, et al. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). J Acquir Immune Defic Syndr 2005; 40(3): 317-323. (Pubitemid 41533072)
43. Schwander S, Rusch Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampidn in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis 1995; 76(3): 210-218.
44. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, GodfreyFaussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358(9294): 1687-1693. (Pubitemid 33124328)
45. Swaminathan S, Deivanayagam CN, Rajasekaran S, et al. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy. Natl Med J India 2008; 21(1): 3-8. (Pubitemid 351420139)
46. Zachariah R, Spielmann MFL, Chinji C, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003; 17(7): 1053-1061. (Pubitemid 36549718)
47. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159(3): 733-740. (Pubitemid 29137767)
48. van Oosterhout JJG, Kumwenda JJ, Beadsworth M, et al. Nevirapinebased antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther 2007; 12(4): 515-521. (Pubitemid 47041150)
49. Schwander SK, Dietrich M, Mugyenyi P, et al. Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. East Afr Med J 1997; 74(9): 543-548. (Pubitemid 127387178)
50. Nsubuga P, Johnson JL, Okwera A, Mugerwa RD, Ellner JJ, Whalen CC. Gender and HIV-associated pulmonary tuberculosis: presentation and outcome at one year after beginning antituberculosis treatment in Uganda. BMC PuIm Med 2002; 2: 4. (Pubitemid 38729371)
51. Chaisson RE, Clermont HC, Holt EA, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154(4 Pt 1): 1034-1108
52. Eholie SP, Domoua K, Kakou A, et al. Outcome of patients with tuberculosis and AIDS in Abidjan (Ivory Coast). Med Mal Infect 1999; 29(11): 697-704.
53. Fitzgerald DW, Desvarieux M, Severe P, Joseph P, Johnson WD Jr, Pape JW. Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. Lancet 2000; 356(9240): 1470-1474.
54. Mukadi YD, Wiktor SZ, Coulibaly IM, et al. Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. AIDS 1997; 11(9): 1151-1158.
55. Olle-Goig JE, Alvarez J. Treatment of tuberculosis in a rural area of Haiti: directly observed and non-observed regimens. The experience of Hopital Albert Schweitzer. Int J Tuberc Lung Dis 2001; 5(2): 137-141. (Pubitemid 32401858)
56. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. J Acquir Immune Defic Syndr 2004; 37(1): 1166-1169. (Pubitemid 39166652)
57. Rodger AJ, Toole M, Lalnuntluangi B, Muana V, Deutschmann P. DOTS-based tuberculosis treatment and control during civil conflict and an HIV epidemic, Churachandpur District, India. Bull World Health Organ 2002; 80(6): 451-456. (Pubitemid 34632821)
58. Rothman KJ, Greenland S. Modern epidemiology. 2nd edition. Lippincott Williams 8c Wilkins, 1998.
59. Driver CR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City. Clin Infect Dis 2001; 33(10): 1762-1769. (Pubitemid 33044545)
60. 60. Theuer CP, Hopewell PC, Elias D, Schecter GF, Rutherford GW, Chaisson RE. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 1990; 162(1): 8-12. (Pubitemid 20223942)
61. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353(9167): 1843-1847. (Pubitemid 29251017)
62. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993; 342(8867): 332-337. (Pubitemid 23227562)
63. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis2006; 41(1): 83-91.
64. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175(11): 1199-1206. (Pubitemid 46855463)
65. Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr 2008; 8: 1. (Pubitemid 351285302)
66. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21(11): 1441-1448. (Pubitemid 46988004)
67. Golub JE, Durovni B, King BS, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22(18): 2527-2533. (Pubitemid 351976707)